Voorhees, P. M., Schlossman, R. L., Gasparetto, C. J., Berdeja, J. G., Morris, J., Jacobstein, D. A., … Richardson, P. G. (2014). An Open-Label, Dose Escalation, Multi-Center Phase 1 Study of PRLX 93936, an Agent Synthetically Active Against the Activated Ras Pathway, in the Treatment of Relapsed or Relapsed and Refractory Multiple Myeloma. In BLOOD (Vol. 124). San Francisco, CA: AMER SOC HEMATOLOGY.

Voorhees, Peter M., Robert L. Schlossman, Cristina J. Gasparetto, Jesus G. Berdeja, John Morris, Douglas A. Jacobstein, Kenneth C. Anderson, Constantine S. Mitsiades, Jacob P. Laubach, and Paul G. Richardson. “An Open-Label, Dose Escalation, Multi-Center Phase 1 Study of PRLX 93936, an Agent Synthetically Active Against the Activated Ras Pathway, in the Treatment of Relapsed or Relapsed and Refractory Multiple Myeloma.” In BLOOD, Vol. 124. AMER SOC HEMATOLOGY, 2014.

Voorhees PM, Schlossman RL, Gasparetto CJ, Berdeja JG, Morris J, Jacobstein DA, et al. An Open-Label, Dose Escalation, Multi-Center Phase 1 Study of PRLX 93936, an Agent Synthetically Active Against the Activated Ras Pathway, in the Treatment of Relapsed or Relapsed and Refractory Multiple Myeloma. In: BLOOD. AMER SOC HEMATOLOGY; 2014.

Voorhees, Peter M., et al. “An Open-Label, Dose Escalation, Multi-Center Phase 1 Study of PRLX 93936, an Agent Synthetically Active Against the Activated Ras Pathway, in the Treatment of Relapsed or Relapsed and Refractory Multiple Myeloma.” BLOOD, vol. 124, no. 21, AMER SOC HEMATOLOGY, 2014.

Voorhees PM, Schlossman RL, Gasparetto CJ, Berdeja JG, Morris J, Jacobstein DA, Anderson KC, Mitsiades CS, Laubach JP, Richardson PG. An Open-Label, Dose Escalation, Multi-Center Phase 1 Study of PRLX 93936, an Agent Synthetically Active Against the Activated Ras Pathway, in the Treatment of Relapsed or Relapsed and Refractory Multiple Myeloma. BLOOD. AMER SOC HEMATOLOGY; 2014.